Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia

International Psychogeriatrics

Volumn 20, Issue 1, 2008, Pages 67-76

  Lorenzl, Stefan ^a,b   Buerger, Katharina ^b   Hampel, Harald ^b   Beal, M Flint ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Alzheimer's disease; Dementia with Lewy bodies; Frontotemporal dementia; Matrix metalloproteases; Mild cognitive impairment; Plasma; Vascular dementia

Indexed keywords

GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

AGED; CONFERENCE PAPER; CONTROLLED STUDY; DEMENTIA; DEMENTIA WITH LEWY BODY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; NEUROPATHOLOGY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; ZYMOGRAPHY;

AGED; ALZHEIMER DISEASE; COGNITION DISORDERS; DEMENTIA; DEMENTIA, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MEMORY DISORDERS; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PICK DISEASE OF THE BRAIN; PLASMA; SEVERITY OF ILLNESS INDEX; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 37149052133     PISSN: 10416102     EISSN: 1741203X     Source Type: Journal    
DOI: 10.1017/S1041610207005790     Document Type: Conference Paper

References (27)

1. Adair, J. C. et al. (2004). Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease. Stroke, 35, 159-162. DOI: 10.1161/01.STR.0000127420. 10990.76
2. Asahina, M., Yoshiyama, Y. and Hattori, T. (2001). Expression of matrix metalloproteinase-9 and urinary-type plasminogen activator in Alzheimer's disease brain. Clinical Neuropathology, 20, 60-63.
3. Backstrom, J. R., Lim, G. P., Cullen, M. J. and Tokes, Z. A. (1996). Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). Journal of Neuroscience, 16, 7910-7919.
4. Brew, K., Dinakarpandian, D. and Nagase, H. (2000). Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochimica et Biophysica Acta, 1477, 267-283. DOI: 10.1016/S0167-4838(99) 00279-4.
5. Frank, R. A. et al. (2003). Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiology of Aging, 24: 521-536. DOI: 10.1016/S0197-4580(03)00002-2.
6. Hampel, H. et al. (2004a). Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer's disease - a comparative CSF study. Archives of General Psychiatry, 61, 95-102.
7. Hampel, H. et al. (2004b). Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity. Journal of Neural Transmission, 111, 247-272. DOI: 10.1007/s00702-003-0065-z.
8. Helbecque, N., Hermant, X., Cottel, D. and Amouyel, P. (2003). The role of matrix metalloproteinase-9 in dementia. Neuroscience Letters, 350, 181-183.
9. Itoh, Y., Ito, A., Iwata, K., Tanzawa, K., Mori, Y. and Nagase, H. (1998). Plasma membrane-bound tissue inhibitor of metalloproteinases (TIMP)-2 specifically inhibits matrix metalloproteinase 2 (gelatinase A) activated on the cell surface. Biological Chemistry, 273, 24360-24367.
10. LaFleur, M. A., Tester, A. M. and Thompson, E. W. (2003). Selective involvement of TIMP-2 in the second activational cleavage of pro-MMP-2: refinement of the pro-MMP-2 activation mechanism. FEBS Letters, 553, 457-463. DOI: 10.1016/S0014-5793(03)01094-9.
11. Leake, A., Morris, C. M. and Whateley, J. (2000). Brain matrix metalloproteinase 1 levels are elevated in Alzheimer's disease. Neuroscience Letters, 291, 201-203. DOI: 10.1016/S0304-3940(00)01418-X.
12. Lee, M. A., Palace, J., Stabler, G., Ford, J., Gearing, A. and Miller, K. (1999). Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain, 122, 191-197.
13. Lorenzl, S. et al. (2003). Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochemistry International, 43, 191-196. DOI: 10.1016/S0197-0186(03) 00004-4.
14. Lund and Manchester Groups (1994). Clinical and neuropathological criteria for frontotemporal dementia. Journal of Neurology, Neurosurgery, and Psychiatry, 57, 416-418.
15. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. and Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 34, 939-944.
16. McKeith, I. G. et al. (2000). Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology, 54, 1050-1058.
17. Morris, J. C. et al. (1989). The consortium to establish a registry for Alzheimer's disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology, 39, 1159-1165.
18. Peress, N., Perillo, E. and Zucker, S. (1995). Localization of tissue inhibitor of matrix metalloproteinases in Alzheimer's disease and normal brain. Journal of Neuropathology and Experimental Neurology, 54, 16-22.
19. Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G. and Kokmen, E. (1999). Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology, 56, 303-308.
20. Pratico, D., Clark, C. M., Liun, F., Rokach, J., Lee, V. Y. and Trojanowski, J. Q. (2002). Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Archives of Neurology, 59, 972-976.
21. Rinaldi, P. et al. (2003). Plasma antioxidants are similary depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiology of Aging, 24, 915-917. DOI: 10.1016/S0197-4580(03)00031-9
22. Rosenberg, G. A., Sullivan, N. and Esiri, M. M. (2001). White matter damage is associated with matrix metalloproteinases in vascular dementia. Stroke, 32, 1162-1168.
23. Sayre, L. M., Smith, M.A. and Perry, G. (2001). Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Current Medical Chemistry, 8, 721-738.
24. Scheuner, D. et al. (1996). Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature Medicine, 2, 864-870.
25. Stix, B., Kahne, T., Sletten, K., Raynes, J., Roessner, A. and Rocken, C. (2001). Proteolysis of AA amyloid fibrils by matrix metalloproteinases- 1, -2, and -3. American Journal of Pathology, 159, 561-570.
26. Vincenti, M. P. (2001). The matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) genes. Transcriptional and posttranscriptional regulation, signal transduction and cell-type-specific expression. Methods in Molecular Biology, 151, 121-148.
27. Yan, P. et al. (2006). Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. Journal of Biological Chemistry, 281, 24566-24574. DOI: 10.1074/jbc.M602440200.